 |
|
Association of Hepatitis C Seropositivity With Increased Risk for Developing End-stage Renal Disease
Judith I. Tsui, MD, MPH;
Eric Vittinghoff, PhD;
Michael G. Shlipak, MD, MPH;
Daniel Bertenthal, MS;
John Inadomi, MD;
Rudolph A. Rodriguez, MD;
Ann M. O’Hare, MD, MA
Arch Intern Med. 2007;167(12):1271-1276.
Background Infection with chronic hepatitis C virus (HCV) has been linked to glomerulonephritis. We undertook this study to determine whether having a positive HCV test result was associated with an increased risk for developing treated end-stage renal disease (ESRD).
Methods Using data from Medicare, the Department of Veterans Affairs, and the United States Renal Data System, we performed a retrospective cohort study of 474 369 adult veterans who had serum creatinine levels measured between October 1, 2000, and September 30, 2001, and HCV antibody testing within 1 year of creatinine testing. Patients were followed up until October 1, 2004, for the outcome of treated ESRD, defined as the onset of chronic dialysis or renal transplantation. Cox proportional hazards models were used to determine the relative hazard for ESRD associated with HCV, adjusted for other covariates (age, sex, race/ethnicity, and comorbidities).
Results Of 474 369 patients in the cohort, 52 874 (11.1%) had a positive HCV antibody test result. Patients with HCV were more likely to develop ESRD: the rate per 1000 person-years was 4.26 (95% confidence interval, 3.97-4.57) for HCV-seropositive patients vs 3.05 (95% confidence interval, 2.96-3.14) for HCV-seronegative patients. For patients aged 18 to 70 years with an estimated glomerular filtration rate of at least 30 mL/min per 1.73 m2, HCV seropositivity was associated with a greater than 2-fold risk for developing ESRD (adjusted hazard rate, 2.80; 95% confidence interval, 2.43-3.23).
Conclusion In this large national cohort of adult veterans, patients younger than 70 years with HCV seropositivity were at increased risk for developing ESRD treated with dialysis or transplantation.
Author Affiliations: Departments of Medicine (Drs Tsui, Vittinghoff, Shlipak, Inadomi, Rodriguez, and O’Hare) and Epidemiology and Biostatistics (Drs Vittinghoff and Shlipak), University of California, San Francisco, Department of Medicine (Drs Tsui, Shlipak, and O’Hare) and Health Services Research and Development Research Enhancement Award Program (Mr Bertenthal), Veterans Affairs Medical Center, and Department of Medicine, San Francisco General Hospital (Drs Inadomi and O’Hare), San Francisco.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis
Feng et al.
Nephrol Dial Transplant 2012;27:640-646.
ABSTRACT
| FULL TEXT
Effects of concomitant hepatitis C virus infection in patients with underlying lupus nephritis on long-term renal outcome
Mitwalli et al.
Nephrol Dial Transplant 2012;27:627-632.
ABSTRACT
| FULL TEXT
Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function
Lee et al.
Nephrol Dial Transplant 2010;25:2772-2785.
ABSTRACT
| FULL TEXT
Chronic viral hepatitis and chronic kidney disease
Chacko et al.
Postgrad. Med. J. 2010;86:486-492.
ABSTRACT
| FULL TEXT
Risk for Renal Cell Carcinoma in Chronic Hepatitis C Infection
Gordon et al.
Cancer Epidemiol. Biomarkers Prev. 2010;19:1066-1073.
ABSTRACT
| FULL TEXT
Hepatitis C Infection and Chronic Renal Diseases
Perico et al.
CJASN 2009;4:207-220.
ABSTRACT
| FULL TEXT
|
